›› 2011, Vol. 31 ›› Issue (1): 39-.doi: 10.3969/j.issn.1674-8115.2011.01.009

• Original article (Clinical research) • Previous Articles     Next Articles

Expression of miR-31 in peripheral blood of patients with systemic lupus erythematosus

FAN Wei1, TANG Yuan-jia2, QU Bo2, CUI Hui-juan2, HUANG Xin-fang1, CHEN Shun-le1, SHEN Nan1,2   

  1. 1.Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai Institute of Rheumatology, Shanghai 200001, China；2.Laboratory of Molecular Rheumatology, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences/Institute of Health Sciences, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China
  • Online:2011-01-28 Published:2011-02-01
  • Supported by:

    National Outstanding Youth Science Foundation of China, 81025016；National High Technology Research and Development Program of China, 863 program, 2007AA02Z123；National Natural Science Foundation of China, 30700734, 30801026, 30971632；Shanghai Natural Science Foundation, 07ZR14130, 10ZR1434900；Key Program of Shanghai Science and Technology Committee, 08JC1414700, 10JC1409300；Shanghai Key Discipline Construction Project, T0203；Shanghai Clinical Research Resource Sharing Platform Project, SHDC12007205

PDF (PC)

1447

Abstract:

Objective To investigate the expression and clinical significance of microRNA (miR-31) in peripheral blood cells of patients with systemic lupus erythmatosus (SLE). Methods Thirty-six patients with SLE and 23 healthy controls were selected, peripheral ACD anti-coagulation blood was obtained, and the expression of miR-31 was detected by RealTime PCR. The relationship between the expression of miR-31 in peripheral blood cells and SLE disease activity index(SLEDAI), parameters of degree of renal injury (Renal-SLEDAI score) and clinical medication was analysed. Results The expression of miR-31 in peripheral blood cells of patients with SLE was significantly lower than that of healthy controls (P<0.001). The expression of miR-31 in peripheral blood cells of patients with SLE was negatively correlated with SLEDAI and Renal-SLEDAI score （r=-0.330，P=0.043；r=-0.337，P=0.044）, while no correlation was found between the expression of miR-31 and clinical medication (P<0.05). Conclusion The expression of miR-31 in peripheral blood cells of patients with SLE may be related to disease activity and degree of renal injury, and may serve as an important biomarker in the early diagnosis, treatment and prognosis assessment of SLE.

Key words: systemic lupus erythmatosus, microRNA, miR-31